on Empyrean Therapeutics, Inc.
Empyrean Therapeutics Acquires Novel Cancer Treatment Molecule
Empyrean Therapeutics, Inc., a biopharmaceutical innovator, has acquired a novel TLR-2 antagonist molecule from Eos Therapies, Inc. This acquisition aims to propel the development of EMS-312, a promising cancer treatment targeting brain, pancreatic, and breast cancers, among others. Currently in the pre-investigational new drug phase, EMS-312 is poised for in vivo validation. Empyrean will utilize its robust R&D infrastructure and global network to advance the molecule towards clinical trials and potential market launch.
According to CEO Kal Fishman, EMS-312 demonstrates strong target affinity, potency, and brain uptake, meeting lead criteria. The acquisition reflects a commitment to rapidly progressing this candidate towards offering new hope to cancer patients globally.
The transaction was finalized in October 2024, with Eos Therapies transferring all intellectual property and research data to Empyrean's labs. The molecule recently secured patents across major global markets.
R. P.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Empyrean Therapeutics, Inc. news